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Background: Less than 20% of patients with follicular lymphoma (FL) present
with Ann Arbor Stage I or II disease at diagnosis. Numerous therapeutic options
exist, however radiation therapy is considered the standard of care for early-
stage disease based on single-institution or retrospective series. Our aim was to
revisit the outcome of patients with localized FL in the rituximab era. Patients and
Methods. We analyzed the characteristics and outcomes of 145 early-stage FL
patients, who were retrospectively divided into six groups according to their initial
treatment: watchful waiting (WW), chemotherapy alone (CT), radiotherapy alone
(RT), combined radiotherapy and chemotherapy (RT-CT), rituximab alone (Ri),
and immunochemotherapy (Ri-CT). Results: Of the 145 patients, 84 (57.9%) had
stage I disease and 61 (42.1%) stage II. The complete response (CR) rate varied
from 57% for the Ri group to 95% for the RT-CT group. Overall survival (OS) at
7.5 y of patients treated after 2000 was bett...
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Abstract
Background: Less than 20% of patients with follicular lymphoma (FL) present with Ann Arbor Stage I or II disease
at diagnosis. Numerous therapeutic options exist, however radiation therapy is considered the standard of care for
early-stage disease based on single-institution or retrospective series. Our aim was to revisit the outcome of
patients with localized FL in the rituximab era.
Patients and Methods: We analyzed the characteristics and outcomes of 145 early-stage FL patients, who were
retrospectively divided into six groups according to their initial treatment: watchful waiting (WW), chemotherapy
alone (CT), radiotherapy alone (RT), combined radiotherapy and chemotherapy (RT-CT), rituximab alone (Ri), and
immunochemotherapy (Ri-CT).
Results: Of the 145 patients, 84 (57.9%) had stage I disease and 61 (42.1%) stage II. The complete response (CR)
rate varied from 57% for the Ri group to 95% for the RT-CT group. Overall survival (OS) at 7.5 y of patients treated
after 2000 was better than that of those treated prior to 2000. OS did not significantly differ from one treatment to
another. In contrast, a significant difference was found for progression-free survival (PFS) at 7.5 y, which favored
Ri-CT (60%) therapy versus the others (p=0.00135).
Conclusion: Delayed therapy initiation was associated with a similar OS than that observed in patients receiving
immediate intervention. The “watchful waiting” strategy may thus be proposed as first-line therapy, similar to stage
III and IV FL patients with a low tumor burden. However, when treatment is required, immunochemotherapy
appears to be the best option.
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Background
Follicular lymphoma (FL) is the most frequently encoun-
tered type of indolent lymphomas. Indolent lymphomas
are considered to be an incurable malignancy with a re-
lapsing and remitting course. For the vast majority of pa-
tients, the disease is managed over many years [1]. Most
patients are diagnosed with FL at an advanced stage, with
<20% presenting with either stage I or II. In the small pro-
portion of patients (15-20%) diagnosed with localized Ann
Arbor stage I or II disease, the treatment of choice re-
mains poorly defined. A wide range of management
options exists, from extended or involved field radiother-
apy, which remained the mainstay treatment [2-4], to the
use of combined radiochemotherapy [5,6] or the “watchful
waiting” approach [7,8]. As there has been no randomized
study, it is difficult to claim that one strategy is better than
another [9]. An Italian expert panel published guidelines
for the management of nodal indolent lymphomas [10].
They recommended involved field (IF) radiotherapy in low
tumor burden localized disease, with adjuvant chemother-
apy being reserved for cases of high tumor burden or
high-risk disease (FLIPI score >2). The experts did not re-
tain the eventuality of a “watchful waiting” option in a low
burden case, which was associated with a good outcome
in the Stanford experience [8]. More recently, a report
mentioned that upfront RT was associated with improved
OS compared with alternate management approaches
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(surveillance, epidemiology and end results database ana-
lysis) [11]. At present, new low-toxicity therapies that pro-
long progression-free survival periods and the interval
period to new anti-lymphoma therapies are available and
include rituximab monotherapy or the combination of ri-
tuximab plus chemotherapy [12]. However, the impact of
current therapies on early Stage FL is still unclear. The im-
portant question concerning the curability of this disease
using a radical treatment remains unanswered.
We report the results of a retrospective study, including
145 patients diagnosed with localized-stage FL (stage I
and II). These patients were treated with one of the six fol-
lowing options as first-line therapy in compliance with the
physician’s decision: watchful waiting (WW), chemother-
apy alone (CT), radiotherapy alone (RT), a combination of
radiotherapy and chemotherapy (RT-CT), immunotherapy
alone (Ri), and immunochemotherapy (Ri-CT). With a
median follow-up period of 7 years, we determined the
clinical characteristics of each group and analyzed the
overall and progression-free survival (OS and PFS) in
order to determine the best approach.
Results and discussion
Of the 145 patients, 84 (57.9%) had Stage I disease and
61 (42.1%) Stage II. Only 22 (15.2%) presented bulky dis-
ease. Twelve patients were classified as having Stage IE
or IIE. FLIPI scoring showed that 93% of the patients
were in the low-risk group with a score of 0–2 (FLIPI
score was 0–1 in 116 pts and 2 in 29 pts) and no patient
had a score of >2.
Patient management significantly varied over the differ-
ent time periods (Figure 1): Period I: <1990; Period II:
1991–2000, and Period III: 2001–2011. RT use decreased
(43% for Period I versus 24% for Period III), whereas
delayed therapy increased from 19.5% for Period I to 75%
for Period III. The use of Ri and Ri-CT increased rapidly
over Period III.
Watchful waiting strategy (WW)
Thirty-six patients (25 females and 11 males) did not re-
ceive any treatment at the time of diagnosis. The median
age was 58 years, with 12 patients (33.3%) aged over 65
years. Twenty-two patients (61.1%) had stage I disease
and 14 (38.9%) stage II disease, while no patients had
bulky disease. Only two of these patients exhibited ab-
normal LDH levels.
Radiation therapy alone (RT)
Twenty-one patients (9 females and 12 males) were
treated with RT alone. The median age was 51 years,
with only four patients (19%) aged over 65 years. Seven-
teen patients (90.5%) had stage I disease and only two
(9.5%) had stage II disease. None of them had bulky dis-
ease. Thirteen patients (65%) had a FLIPI score of 0, and
five (30%) had a score of 1. No patient exhibited elevated
β2-microglobulin levels or abnormal LDH levels. Five
patients received extended RT and 16 received IF radio-
therapy. Radiation doses ranged from 40 to 50Gy.
Chemotherapy alone (CT)
Twenty-six patients (12 females and 14 males) were treated
with CT alone. The median age was 52.5 years, with eight
patients (31%) aged over 60 years. Nine patients (34.6%)
had stage I disease and 17 (65.4%) stage II, and the majority
(17 patients) had no bulky disease. Twenty patients (77%)
had normal LDH levels. In terms of the chemotherapy
regimen, all patients received an anthracycline-containing
regimen (CHOP or CHOP-like regimen).
Figure 1 Repartition of treatment over time (% of patients). Three time intervals: Period I: <1990, Period II: 1991–2000, and Period
III: 2001–2011.
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Immunotherapy (Ri)
Only seven patients (4 females and 3 males) were treated
with Ri alone as the single agent. Four injections were ad-
ministered weekly with no further maintenance. The me-
dian age was 55 years, with 28.6% being older than 65.
Three patients had stage I disease and four stage II. The
majority of the patients had no bulky disease (71.4%).
Combination of chemotherapy and radiotherapy (CT-RT)
Eighteen patients (10 females and 9 males) were treated
with various CT regimens (CHOP and CHOP-like regi-
mens) plus RT. The median age was 51 years; none of
these patients were older than 60 years. Seventeen
(89.5%) had stage I disease and only 2 (10.5%) had stage
II. The majority of patients (95%) had no bulky disease
with a FLIPI score of 0. Fourteen patients had normal
LDH levels. Three patients received additional extended
RT, and 15 patients were given IF radiotherapy.
Immunochemotherapy (Ri-CT)
Thirty-six (17 males and 19 females) were treated with
the combination of both Ri and CT, principally with the
CHOP regimen. The median age was 56 years with only
four patients being older than 65. Fifteen (41.7%) pa-
tients had bulky disease, and 17% had an abnormal LDH
level at the time of diagnosis. Twenty-two patients had
stage II (61%) disease and 14 stage I (39%).
Comparison of the six groups
Median age, sex ratio, number of patients over 60 years,
stage of disease, and LDH levels were analyzed for the
six groups (Table 1). There was a significant difference
in terms of disease stage when comparing the RT based
group (RT and RT+CT) group against the Ri based
group (Ri-CT and Ri) with a large majority (90%) of
Stage I disease in the RT-based groups (p=0,018) with-
out any bulky disease (p= 0,05). Finally, the Ri-CT group
had a higher number of adverse features: 41.7% of bulky
disease and 16.7% of abnormal LDH levels.
Response rates and disease progression
The CR rate varied from 57.1% for Ri to 95% for the RT-
CT group, with 69% for CT, 75% for Ri-CT, and 81% for
RT alone, as shown in Table 2. As expected, the propor-
tion of the PR was higher in the Ri group (43%). With a
median follow-up interval of 7 years, the relapse rate was
significantly lower in the Ri-CT group (40%) versus the
RT-based group (90.5% for RT, 84% for RT-CT; p= 0,048);
and 69% for CT as shown in Table 2.
Overall survival and progression-free survival
According to the changes in treatment management
over time, OS, and PFS were analyzed for two periods of
time (associated to the rituximab era): < the year 2000
and > or = 2000. As shown in Figure 2A and 2B, there
was no difference in terms of OS or PFS at 5 years for
the two time periods (85% vs. 87% and 48% vs. 42% re-
spectively). Finally, we have shown a trend to a better
OS at 7.5 years for the patients treated after 2000 (75%)
than that for those treated <2000 (59%) but this differ-
ence is not statistically significant (p=0.29).
When considering PFS and OS according to the type
of treatment, analyses did not show any difference in
terms of OS at 7.5 years: 72% WW, 74% CT, 74% Ri-CT,
Table 1 Clinical characteristics of the population according to type of treatment
W and W CT Ri-CT RT-CT RT Ri
Number 36 26 36 19 21 7
Median age 58 52.5 56 51 51 55
>65 years 12 (33.3%) 8 (30.8%) 4 (11.1%) 0 (0%) 4 (19%) 2 (28.6%)
Gender
M 11 (30.6%) 14 (53.8%) 17 (47.2%) 9 (47.4%) 12 (57.1%) 3 (42.9%)
F 25 (69.4%) 12 (46.2%) 19 (52.8%) 10 (52.6%) 9 (42.9%) 4 (57.1%)
Stage
I 22 (61.1%) 9 (34.6%) 14 (38.9%) 17 (89.5%) 19 (90.5%) 3 (42.9%)
II 14 (38.9%) 17 (65.4%) 22 (61.1%) 2 (10.5%) 2 (9.5%) 4 (57.1%)
Bulky
No 36 (100%) 17 (65.4%) 20 (55.5%) 18 (94.7%) 21 (100%) 5 (71.4%)
Yes 0 4 (15.4%) 15 (41.7%) 1 (5.3%) 0 (0%) 2 (28.6%)
LDH
N N 31 (86.1%) 27 (75%) 14 (73.7%) 11 (52.4%) 7 (100%)
> N > N 1 (3.9%) 6 (16.7%) 2 (10.5%) 0 (0%) 0 (0%)
WW watchful waiting, CT chemotherapy, RT-CT radiotherapy and chemotherapy.
Ri: immunotherapy, and Ri + CT: immune-chemotherapy.
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67% RT-CT, 66% RT, and 100% Ri. By contrast, a signifi-
cant difference was found for PFS at 7.5 years in favor of
Ri-CT (60%) versus the others (19% RT, 26% RT-CT,
23% CT, and 26% for the WW strategy; p=0.00135), as
shown in Figure 3.
Follicular lymphomas are slow-growing tumors with a
relapsing and remitting course following treatment and
usually result in death from the illness after several
years. Although spontaneous regression may occur and
progression may be slow, approximately 50% of patients
undergo histological transformation to a more aggressive
lymphoma with a poor prognosis [13]. In early-stage FL,
the prospect of curing or, at least, maintaining long
relapse-free survival often leads to treatment initiation
[14]. On the other hand, the long life-expectancy of
these patients, in spite of the disease, encourages treat-
ment side-effects to be minimized as much as possible
[6]. Nevertheless, while approximately 15 to 30% of pa-
tients with nodal or extra-nodal FL present clinical Stage I
or II disease, therapy for early-stage FL offers a large num-
ber of possibilities: watchful waiting, single agent alkylating
therapy, radiation therapy, CHOP regimen, and rituximab
with various possible combinations. Defining the standard
of care remains complex. In this retrospective study, we
classified patients into six groups according to the treat-
ments administered: abstention or delayed therapy, chemo-
therapy alone, radiotherapy alone, a combination of
chemotherapy and radiotherapy, immunotherapy, and
immunochemotherapy. RT alone is considered as the
mainstay treatment showing long survival in some studies
[3-5,15]. With a median follow-up period of 8 to 19 years,
retrospective studies on RT have shown a 10-year PFS rate
of 45% and 10-year OS rate of 65 to 75% [2,3,16,17]. These
results do not differ from those observed in this analysis in
terms of OS at 10 years (66% for the RT group and 62% for
the RT-CT group). On the other hand, in our study, the
PFS rate was lower than that reported in literature (around
25%); except for immunochemotherapy (60% PFS at 7.5
years) [3,16,17]. One explanation is the inherent limits of
the retrospective setting and that some patients were re-
ferred to our center at the time of relapse.
The two issues surrounding radiation are field size and
dose. The vast majority of early FL patients treated in
retrospective series demonstrated excellent PFS following
RT with involved field radiation, with a minority receiving
extended field radiation. Recently, a randomized con-
trolled trial of low- versus high-dose RT [18] for indolent
non-Hodgkin’s lymphoma demonstrated an equivalence of
the two indolent lymphomas including early-stage FL with
Table 2 Response to treatment, disease progression, and
survival
W and W CT Ri-CT RT-CT RT Ri
Responses
CR 69.2% 75% 94.7% 80.9% 57.1%
PR 19.2% 16.7% 5.3% 9.5% 42.9%
SD 0 2.8% 0 0 0
PD 11.6% 5.5% 0 9.5% 0
Relapse rate - 69.2% 38.9% 84.2% 90.5% 42.9%
Median PFS 7,5 y 26% 23% 60% 26% 19% -
Median OS 7.5y 72% 74% 74% 67% 66% 100%
CR complete response, PR partial response, SD stable disease, PD progressive
disease, OS overall survival, PFS progression free survival.
A. B.
Figure 2 Disease progression and survival according to the period of time. A. Overall survival (OS) for two periods of time: <year 2000 and
> or equal to 2000. B. Progression free survival (PFS) for to two periods of time, < 2000 and > or equal to 2000.
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respect to response rate, PFS, and OS. Additionally, the
prospective multicenter MIR (Mabthera and Involved field
Radiation) study, which combines anti-CD20 antibody ri-
tuximab in combination with involved field radiotherapy
(30–40 gray), evaluates the efficacy of rituximab in
preventing out-filed recurrences as well as the safety of
this combination [19].
Very few studies have looked at CT alone in localized
FL [20]. As in our study, PFS did not differ for patients
who received CT with or without RT (PFS at 7.5 years
23% for CT vs. 26% for combination RT-CT). The major
question is whether immunochemotherapy improves the
outcome for patients with early-stage FL. A recent analysis
conducted by the National LymphoCare Study revealed, in
a large prospectively enrolled group of patients with Stage
I FL, that PFS was significantly improved with either
rituximab-CT or systemic therapy plus RT when com-
pared to RT alone [21].
Conclusion
One interesting observation in our study was that delayed
therapy was associated with a similar outcome than that
observed in treated patients (OS at 7.5 years for the differ-
ent treatments and WW did not show any difference: 72%
for WW compared to 74% for Ri-CT and 67% for RT-CT).
This observation was previously reported in two retro-
spective studies [7,8]; the watchful waiting approach may
thus be a reasonable strategy that does not affect OS (85%
at 10 years) [22]. These results demonstrate that the
choice of first-line treatment has no influence on the
course of the disease, in contrast to patients receiving
cytotoxic therapy, where the addition of rituximab im-
proves OS [23]. However, when treatment is required,
combined immunochemotherapy appears to be the best
option. According to Montoto [24] and Friedberg et al.
[21], the question of standard treatment in localized FL re-
mains unresolved and requires well-designed randomized
clinical trials.
Patients and methods
Patient characteristics
We analyzed 145 patients (pts) (79 females and 66 males),
with a median age of 55 years (20% of patients aged >65
years) and a diagnosis of early-stage FL made between
January 1967 and January 2011. All of these patients are
either untreated patients with a diagnosis of FL made in
our unit or refered to our unit in the relapse setting. With
a median follow-up interval of 7 years and one month,
diagnosis was based, in all cases, on a surgical specimen
(lymph node or extra-nodal site biopsy). Histological re-
ports provided the diagnosis in accordance with the
World Health Organization (WHO) classification system.
Patients with a histological WHO classification Grade 3b
were excluded, as most experts would recommend a man-
agement plan identical to that of diffuse large B-cell
lymphoma (DLBCL) [25].
Figure 3 Progression free survival (PFS) according to type of treatment.
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Staging was designated according to the Ann Arbor sys-
tem with “bulky disease” recording (>7 cm). Initial staging
included a thoracic and abdominal CT scan, and a bone
marrow aspirate and biopsy. PET CT has only been used
in recent years. A complete blood count and routine blood
chemistry testing, including LDH and β2-microglobulin
levels, were performed. The Follicular Lymphoma Inter-
national Prognostic Index (FLIPI) score was calculated
based on individual parameters [26]. This index is based
on five parameters with a poor outcome associated with
age ≥60 years, hemoglobin <12 g/dl, LDH above normal
range, Stage III/IV disease, and presence of >4 nodal sites,
which is subdivided into low (0–1), intermediate (2), and
high (≥3) risk groups.
Patients were retrospectively divided into six groups
according to the initial therapeutic strategy that was ap-
plied: WW, CT alone, RT alone, RT-CT, Ri alone, and
Ri-CT. The initial treatment was decided upon by the at-
tending physician following discussion with the patient.
Clinical and biological patient characteristics are sum-
marized in Table 1.
Statistical analysis
Statistical analyses were performed using SPSS software
version 12.0. Demographic characteristics were compared
across the groups using chi-squared tests for qualitative
characteristics, while the t-test, Mann–Whitney test, and
ANOVA test were used for quantitative characteristics.
The event-free survival (EFS) and the OS were calculated
according to the Kaplan-Meier product limit estimator
method. Survival was calculated from the time of diagno-
sis to death for any given case. PFS was calculated from
the time of diagnosis to the moment of progression or re-
lapse. Univariate comparisons of survival curves were
made using the log-rank test. Two side P-values of <0.05
were considered statistically significant.
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